P-tau and neurodegeneration mediate the effect of β-amyloid on cognition in non-demented elders

Table 1 Clinical characteristics of participants in individual groups in the current study

	CN (n = 370)	MCI (n = 623)	p value
Age (years)	73.78 ± 5.91	72.42 ± 7.53	0.012
Gender (F/M)	194/176	256/366	0.001
Education (years)	16.39 ± 2.62	16.05 ± 2.76	0.081
APOE ε4 carriers (%)	27.84%	49.12%	< 0.001
CSF measures
Aβ₄₂	200.34 ± 50.95	171.70 ± 52.28	< 0.001
p-tau	32.13 ± 18.40	39.07 ± 22.38	< 0.001
t-tau	67.51 ± 32.16	90.56 ± 54.82	< 0.001
Neurogranin	379.95 ± 284.78	508.58 ± 343.28	< 0.001
sTREM2	4104.09 ± 2122.88	4448.60 ± 2285.17	0.508
YKL-40	392.56 ± 127.99	393.71 ± 131.49	0.966
Plasma NFL	34.32 ± 21.96	39.20 ± 22.85	< 0.001
MRI measures
Whole brain	1040346.1 ± 104238.7	1047243.7 ± 109038.5	0.411
Hippocampus	7467.2 ± 851.0	6867.8 ± 1142.1	< 0.001
Entorhinal	3854.9 ± 610.2	3553.4 ± 724.3	< 0.001
Mid temporal	20342.2 ± 2649.5	19895.1 ± 2860.6	0.051
Cognitive composite measures
Memory function	1.05 ± 0.57	0.20 ± 0.69	< 0.001
Executive function	0.79 ± 0.82	0.23 ± 0.88	< 0.001
Language	0.81 ± 0.71	0.21 ± 0.77	< 0.001
Visuospatial functioning	0.20 ± 0.60	− 0.06 ± 0.75	< 0.001

Categorical variables are reported as numbers and percentages; continuous variables are reported as means ± SDs
Abbreviations: CN normal controls, MCI mild cognitive impairment, M male, F female, APOE ε4 apolipoprotein E4, CSF cerebrospinal fluid, Aβ amyloid-β, p-tau phosphorylated tau, t-tau total tau, sTREM2 soluble triggering receptor on myeloid cells 2, NFL neurofilament light, MRI magnetic resonance imaging

ISSN: 1758-9193